A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy ( STEADFAST )
Year: 2026
Type: article
Source: American Journal of Hematology
DOI: 10.1002/ajh.70447
Institutions: University of Tennessee Health Science Center, Université Paris-Est Créteil, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, University of Illinois Chicago, University of North Carolina at Chapel Hill, Nini Hospital, University of Alabama at Birmingham, Hospital Samaritano de São Paulo, University of Nottingham, King's College Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,450
Funder: Novartis Pharma
OpenAlex ID: W7169513554